CD95 (Fas) ligand expression of Epstein-Barr virus (EBV)-infected lymphocytes: A possible mechanism of immune evasion in chronic active EBV infection

Pathology International

Volumn 49, Issue 1, 1999, Pages 9-13

  Ohshima, Koichi ^a   Suzumiya, Junji ^a   Sugihara, Midori ^a   Nagafuchi, Seiho ^b   Ohga, Shouichi ^c   Kikuchi, Masahiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b First Department of Internal Medicine   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Chronic active Epstein Barr virus infection; Epstein Barr virus; Fas, Fas ligand

Indexed keywords

CD56 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GRANZYME A; PERFORIN;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CHILD; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTIOUS MONONUCLEOSIS; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

EID: 0032845508     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.1999.00816.x     Document Type: Article

References (19)

1. Isaacs R. Chronic infectious mononucleosis. Blood 1948; 3: 858-861.
2. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexpected illness: Elevated anti-early antigen antibodies. Ann. Intern. Med. 1985; 102: 1-7.
3. Rickinson AB. Chronic, symptomatic Epstein-Barr virus infection. Immunol. Today 1986; 7: 13-14.
4. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 1989; 32: 502-506.
5. Kawa-Ha K, Ishihara S, Ninomiya T et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J. Clin. Invest. 1989; 84: 51-55.
6. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr. 1995; 84: 1271-1275.
7. Purtilo DT, Strobach RS, Okano M, Davis JR. Biology of disease. Epstein-Barr virus-associated lymphoproliferative disorders. Lab. Invest. 1992; 67: 5-23.
8. Kägi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
9. Shiver JW, Su L, Hankart PA. Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 1992; 71: 315-322.
10. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 1993; 177: 195-200.
11. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
12. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induce by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nature Med. 1996; 2: 1361-1366.
13. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-632.
14. Ohshima K, Fujisaki T, Nagafuchi S, Niho Y, Kobari S, Kikuchi M. Malignant histiocytosis derived from a common histiocyte clone in a patient with chronic Epstein-Barr virus infection. Leukemia Lymphoma 1995; 17: 355-360.
15. Weiss LM, Jaffe ES, Liu XF, Chan YY, Shibata D, Medeiros J. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79: 1789-1795.
16. Fujieda M, Wakiguchi H, Hisakawa H, Kubota H, Kurashige T. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents. Acta Paediatr. Jpn. 1993; 35: 394-399.
17. Anderson P, Nagler-Anderson C, O'Brien C et al. A monoclonal antibody reactive with a 15 kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. J. Immunol. 1990; 42:1194-1198.
18. Medley QG, Kedersha N, O'Brien S, Tian Q. Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition. Proc. Natl Acad. Sci. USA 1996; 93: 685-689.
19. Kundu SK, Menezes J. Interleukin 2-induced killer cell activity against Epstein-Barr virus-immortalized human B-cells. Immunol. Lett. 1989; 20: 299-304.